Virax Biolabs rises on COVID, influenza rapid test launch deal
07/02/2023 16:52
** Shares of biotech company Virax Biolabs Group Ltd
VRAX.O rise 8.5% to $0.89
** VRAX signs purchase order with Cosmos Health Inc COSM.O
to launch and market COVID-19 and influenza antigen combo rapid
detection kits
** The rapid test is a single-use test kit intended for
qualitative detection of influenza A and B viral antigens and
COVID-19 antigen from nasal swab specimens - VRAX
** VRAX stock up 21.8% so far in 2023
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com))